Al Mashadi’s study, which compares the risk of major osteoporotic fractures (MOFs) in patients on GLP-1RAs therapy versus those on dipeptidyl peptidase-4 inhibitor (DPP-4i) therapy, indicates that GLP-1RAs users have a significantly lower risk of hip fracture and a reduced risk of MOFs compared to DPP-4i users [22]. This evidence concerns the gene DPP4 and hip fracture.